CMPX Stock — Compass Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.90

Market cap

$342.2M

Cash

$179.9M

Enterprise value

$162.3M

Balance sheet

Cash	$179.9M
Debt	$0.0M
Net cash	$179.9M
Enterprise value	$162.3M
Basic shares	180.1M shares
Fully diluted shares	204.8M shares
Fully diluted market cap	$389.1M
Cash per share	$1.00

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CMPX daily closes…

Loading price history…

Pipeline assets

Tovecimig

Phase 2/3 · Active Modality: Bispecific antibody

Aliases CTX-009

Target DLL4 x VEGF-A

Partnerships ABL Bio (Nov 2018): exclusive global license excluding South Korea; jointly developed; ABL Bio responsible through end of Phase 1; eligible for up to $96M development/regulatory + $303M commercial milestones (oncology), tiered single-digit royalties

Indications

Biliary tract cancer (BTC), 2L, + paclitaxel (Phase 2/3)
BTC, 1L, investigator-sponsored (+ gemcitabine/cisplatin/durvalumab) (Phase 2/3)
Colorectal cancer, 3L/4L monotherapy (Phase 2)

Catalysts

— Q3 2026
— 2026

Status note COMPANION-002 Phase 2/3 trial in second-line biliary tract cancer (with paclitaxel) completed; survival and safety data announced April 2026.

CTX-471

Phase 1 · Active Modality: Agonistic antibody

Target CD137 (4-1BB)

Indications

Solid tumors incl. melanoma, SCLC, mesothelioma; Phase 2 basket in NCAM+ tumors planned (Phase 1)

Status note CD137 (4-1BB) agonist; Phase 1 ongoing.

CTX-8371

Phase 1 · Active Modality: Bispecific antibody

Target PD-1 x PD-L1

Indications

TNBC, Hodgkin lymphoma, NSCLC (metastatic/locally advanced) (Phase 1)

Catalysts

— Q4 2026

Status note First-in-human Phase 1 ongoing.

CTX-10726

Phase 1 · Active Modality: Bispecific antibody

Target PD-1 x VEGF-A

Indications

RCC, gastroesophageal, HCC, endometrial (locally advanced/metastatic) (Phase 1)

Catalysts

— 2026 (Q4)

Status note IND cleared early 2026; Phase 1 dose escalation underway.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06548412	Phase 2	Recruiting	Collaborator	M.D. Anderson Cancer Center	—	Metastatic Biliary Tract Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for M.D. Anderson Cancer Center on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	15,219,994	no change	0.63%	2026-08-14
ADAR1 Capital Management	122,132	-16,868	0.01%	2026-08-14
Ikarian Capital	18,000	no change	0.01%	2026-08-14
RTW Investments	0	-4,186,599	0.00%	2026-08-14
Braidwell LP	0	-1,965,106	0.00%	2026-08-14
Logos Global Management	0	-3,150,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CMPX — Compass Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials

Institutional holders